LY2811376 50mg 50mg | Purity Not Available
Adooq Bioscience
LY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageLY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.
More Information Supplier PageAzilsartan (TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension.
More Information Supplier PageAzilsartan (TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension.
More Information Supplier PageAzilsartan (TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension.
More Information Supplier PageSL-251188, an oxazolidinone derivative, was characterized in baboons as a radioligand for the in vivo visualization of MAO-B using positron emission tomography (PET).
More Information Supplier PageSL-251188, an oxazolidinone derivative, was characterized in baboons as a radioligand for the in vivo visualization of MAO-B using positron emission tomography (PET).
More Information Supplier Page